Search Results - "Bril, Vera"

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study.

Authors: Mielke, Orell Bril, Vera Cornblath, David R. et al.

Source: Journal of the Peripheral Nervous System. Mar2019, Vol. 24 Issue 1, p72-79. 8p.

Variability in Conduction Block Definitions Affects the Sensitivity of Diagnostic Criteria for Multifocal Motor Neuropathy.

Authors: Gonçalves, Lucas Immich Bril, Vera

Source: Journal of the Peripheral Nervous System. Jun2025, Vol. 30 Issue 2, p1-2. 2p.

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis.

Authors: Habib, Ali A. Claeys, Kristl G. Bril, Vera et al.

Source: Annals of Clinical & Translational Neurology. Jun2025, Vol. 12 Issue 6, p1162-1170. 9p.

Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.

Authors: Lewis, Richard A. Cornblath, David R. Hartung, Hans‐Peter et al.

Source: Journal of the Peripheral Nervous System. Sep2020, Vol. 25 Issue 3, p230-237. 8p.

Hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE‐CIDP 1 randomized controlled trial.

Authors: Bril, Vera Hadden, Robert D. M. Brannagan, Thomas H. et al.

Source: Journal of the Peripheral Nervous System. Sep2023, Vol. 28 Issue 3, p436-449. 14p.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Authors: Merkies, Ingemar S.J. van Schaik, Ivo N. Léger, Jean‐Marc et al.

Source: Journal of the Peripheral Nervous System. Mar2019, Vol. 24 Issue 1, p48-55. 8p.

Intra-familial variability of oculoleptomeningeal amyloidosis due to the ATTR I107M (c.381T > G) mutation: diagnostic challenges of a rare phenotype.

Authors: Alcantara, Monica Bril, Vera

Source: Amyloid. Mar2024, Vol. 31 Issue 1, p70-72. 3p.

Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension.

Authors: Nowak, Richard J. Breiner, Ari Bril, Vera et al.

Source: Annals of Clinical & Translational Neurology. Jan2024, Vol. 11 Issue 1, p194-206. 13p.

Electrophysiological grading scale for polyneuropathy severity.

Authors: Abraham, Alon Bril, Vera

Source: PLoS ONE. 5/22/2024, Vol. 19 Issue 5, p1-7. 7p.

Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial.

Authors: Hadden, Robert D. M. Andersen, Henning Bril, Vera et al.

Source: Journal of the Peripheral Nervous System. Dec2024, Vol. 29 Issue 4, p441-452. 12p.

Systematic Comparison of Muscle Ultrasound Thickness in Polyneuropathies and Other Neuromuscular Diseases.

Authors: Alnajjar, Sara A. Fathihelabad, Davood Abraham, Alon et al.

Source: Neurology & Therapy. Oct2023, Vol. 12 Issue 5, p1623-1630. 8p.

Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.

Authors: Merkies, Ingemar S. J. van Schaik, Ivo N. Bril, Vera et al.

Source: Journal of the Peripheral Nervous System. Jun2022, Vol. 27 Issue 2, p159-165. 7p.

Acute Intermittent Porphyria: A Report of 3 Cases with Neuropathy.

Authors: Alqwaifly, Mohammed Bril, Vera Dodig, Dubravka

Source: Case Reports in Neurology. 2019, Vol. 11 Issue 1, p32-36. 5p.

FcRn Inhibitor Therapies in Neurologic Diseases.

Authors: Alfaidi, Nouf Karmastaji, Salama Matic, Alexandria et al.

Source: CNS Drugs. Jun2024, Vol. 38 Issue 6, p425-441.

Hereditary transthyretin amyloidosis: a case report.

Authors: Lee, Angela Fine, Nowell M. Bril, Vera et al.

Source: Journal of Medical Case Reports. 6/25/2022, Vol. 16 Issue 1, p1-5. 5p.

IVIG and PLEX in the treatment of myasthenia gravis.

Authors: Bril, Vera Barnett‐Tapia, Carolina Barth, David et al.

Source: Annals of the New York Academy of Sciences. Dec2012, Vol. 1275 Issue 1, p1-6. 6p. 1 Chart, 1 Graph.

Reply to letter in response to Rethinking the diagnosis of double‐seronegative myasthenia gravis.

Authors: Martinez‐Harms, Rodrigo Barnett, Carolina Alcantara, Monica et al.

Source: European Journal of Neurology. Mar2024, Vol. 31 Issue 3, p1-2. 2p.

Subjects: Myasthenia gravis, Pathology, Diagnosis, Nicotinic acetylcholine receptors

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.

Authors: Tortorici, Michael A. Yuraszeck, Theresa Cornblath, David et al.

Source: CPT: Pharmacometrics & Systems Pharmacology. Aug2021, Vol. 10 Issue 8, p839-850. 12p.

Electrophysiological Responsiveness to Long-Term Therapy in Chronic Inflammatory Demyelinating Polyneuropathy: Case Report.

Authors: Khomand, Payam Katzberg, Hans Ngo, Mylan et al.

Source: Case Reports in Neurology. 2020, Vol. 12 Issue 1, p40-44. 5p.

Author Index.

Source: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2025 Supplement 1; Vol. 52 (S1).

Journal Info: Publisher: Cambridge University Press ISSN: 0317-1671